Delta-Fly Pharma, Inc.

TSE:4598 Stock Report

Market Cap: JP¥5.3b

Delta-Fly Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Kiyoshi Eshima

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership9.9%
Management average tenureno data
Board average tenure7yrs

Recent management updates

Recent updates

We're A Little Worried About Delta-Fly Pharma's (TSE:4598) Cash Burn Rate

Sep 06
We're A Little Worried About Delta-Fly Pharma's (TSE:4598) Cash Burn Rate

Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

May 22
Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

CEO

Kiyoshi Eshima (75 yo)

no data

Tenure

Mr. Kiyoshi Eshima, Ph.D. is the Founder of Delta-Fly Pharma, Inc. and served as President and Director. He is President & Representative Director of Delta-Fly Pharma, Inc.

Board Members

NamePositionTenureCompensationOwnership
Kiyoshi Eshima
President & Representative Directorno datano data9.88%
¥ 519.8m
Kinichiro Kominami
Independent Outside Director6.5yrsno datano data
Kenzo Iizuka
Director11.8yrsno data0.92%
¥ 48.4m
Sachio Kishii
Independent Outside Director7.5yrsno datano data
Masaya Kimura
Auditor10.5yrsno data0.16%
¥ 8.6m
Shohei Yamamoto
External Auditor9.8yrsno datano data
Kenichi Kurotaki
Director4.5yrsno datano data
Akifumi Taniguchi
Independent Outside Director3.5yrsno datano data
Masaaki Maeda
Full-Time Auditor4.5yrsno datano data

7.0yrs

Average Tenure

59yo

Average Age

Experienced Board: 4598's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 14:12
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Delta-Fly Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kiyokazu YamazakiIchiyoshi Research Institute Inc.